What's Going On With Allurion Stock On Wednesday?

Allurion Technologies, Inc. (NYSE:ALUR) shares fell on Wednesday after the gastric balloon maker announced a discounted warrant exercise, raising concerns about dilution.

On Tuesday, Allurion said it will immediately exercise certain outstanding warrants at a reduced price of $1.15 per share. The move generates approximately $3 million in gross proceeds. The company entered into a definitive agreement covering about 2.66 million shares, with closing expected on or around Feb. 25.

As part of the transaction, Allurion also agreed to file a resale registration statement with the SEC covering up to 5.32 million shares underlying new warrants issued in the private placement, also exercisable at $1.15 per share.

The broader market and technology sector both rose in the prior session. This suggests that company-specific factors drove the stock's decline.

Recent FDA Nod Sparks Weight-Loss Buzz

The latest development follows the company's U.S. Food and Drug Administration premarket approval (PMA) application for the Allurion Gastric Balloon System on Feb. 23, which features the Allurion Smart Capsule.

"Today's approval is a watershed moment for Allurion and for obesity care in the United States," said Dr. Shantanu Gaur, founder and CEO. "Our goal is to deliver patients metabolically healthy weight loss by helping them lose weight, keep it off, and maintain muscle."

Gaur added that the Allurion Smart Capsule offers "a safe and effective alternative to GLP-1s and bariatric surgery," and said it "should become a standard tool in the comprehensive treatment of obesity in the United States."

Technical Analysis

The stock is currently trading 8.5% below its 20-day simple moving average (SMA) and 12.3% below its 100-day SMA, suggesting a bearish trend in the short to medium term. Shares have decreased by 68% over the past 12 months and are currently positioned closer to their 52-week lows than highs.

The RSI is at 50.00, indicating a neutral position, while the MACD is at 0.00, below its signal line at 0.10, suggesting bearish pressure on the stock. The combination of neutral RSI and bearish MACD indicates mixed momentum.

• Key Resistance: $1.50
• Key Support: $1.00

Earnings & Analyst Outlook

NYSE:ALUR is slated to provide its next financial update on March 25, 2026.

• EPS Estimate: Loss of 51 cents (Up from -795 cents YoY)
• Revenue Estimate: $2.95 million (Down from $5.59 million YoY)

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $48.50. Recent analyst moves include:

• Chardan Capital: Upgraded to Buy (Raises Target to $3.00) (Feb. 24)

ALUR Price Action: Allurion Technologies shares were down 2.21% at $1.33 during premarket trading on Wednesday.

Image: Shutterstock